Literature DB >> 8643248

The one-year surgical outcome after prism adaptation for the management of acquired esotropia.

M X Repka1, J E Connett, W E Scott.   

Abstract

PURPOSE: To report the 1-year motor and sensory outcomes for patients with acquired comitant esotropia managed with preoperative prism adaptation.
METHODS: Patients entered a multicenter randomized prospective evaluation of prism adaptation before strabismus surgery. Prism responders were randomized to surgery with the target angle based on either the entry angle or the adapted angle of esotropia. Three hundred five patients (92 percent of cohort) completed 1-year postoperative follow-up.
RESULTS: The overall motor success rate for all patients in the study was 74 percent. Prism responders operated on for the adapted esotropic target angle had a satisfactory motor outcome more often than those operated on for the entry angle, 90 percent compared with 75 percent (P = 0.04). Significant predictors of a satisfactory motor outcome after surgery were prism adaptation, female sex, and hyperopia greater than or equal to +3.00 D. Prism responders operated on for the adapted angle showed fusion of the Worth 4-dot at substantially more often than did those operated on for the entry angle, 75 percent compared with 60 percent (P = 0.12).
CONCLUSION: Prism adaptation significantly improves the 1-year motor outcome after esotropia surgery in prism responders. There is no increase in the number of overcorrections. These results confirm the value of allotting the extra time and potential expense needed for this technique.

Entities:  

Mesh:

Year:  1996        PMID: 8643248     DOI: 10.1016/s0161-6420(96)30586-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Re-alignment of the eyes, with prisms and with eye surgery, affects postural stability differently in children with strabismus.

Authors:  Agathe Legrand; Emmanuel Bui-Quoc; Maria Pia Bucci
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-10-28       Impact factor: 3.117

Review 2.  Distance-near disparity esotropia: can we shrink the gap?

Authors:  J P Burke
Journal:  Eye (Lond)       Date:  2014-11-14       Impact factor: 3.775

3.  Risk factors associated with poor outcome after medial rectus resection for recurrent intermittent exotropia.

Authors:  Jihei Sara Lee; Jinu Han; Sueng-Han Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-19       Impact factor: 3.117

4.  Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin.

Authors:  J Tejedor; J M Rodríguez
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

5.  Clinical characteristics and surgical outcomes of adults with acute acquired comitant esotropia.

Authors:  Haeng-Jin Lee; Seong-Joon Kim
Journal:  Jpn J Ophthalmol       Date:  2019-09-23       Impact factor: 2.447

6.  Retreatment of children after surgery for acquired esotropia: reoperation versus botulinum injection.

Authors:  J Tejedor; J M Rodríguez
Journal:  Br J Ophthalmol       Date:  1998-02       Impact factor: 4.638

7.  Comparison of the therapeutic effects of surgery following prism adaptation test versus surgery alone in acute acquired comitant esotropia.

Authors:  Peng Zhang; Ying Zhang; Lei Gao; Jun Yang
Journal:  BMC Ophthalmol       Date:  2020-07-23       Impact factor: 2.209

8.  Treatment of acute acquired concomitant esotropia.

Authors:  Minghua Shi; Yuanxiang Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2021-01-06       Impact factor: 2.209

9.  Long-term outcomes of prismatic correction in partially accommodative esotropia.

Authors:  Hye Rim Choe; Hee Kyung Yang; Jeong-Min Hwang
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

10.  Clinical Characteristics of Patients with Intermittent Exotropia According to the Response to Short-term Prism Adaptation Test.

Authors:  Young In Yun; Seong-Joon Kim; Jae Ho Jung
Journal:  Korean J Ophthalmol       Date:  2020-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.